Skip to main content
Top
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | SARS-CoV-2 | Research

Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022

Authors: Håkon Bøås, Margrethe Larsdatter Storm, German Tapia, Anja Bråthen Kristoffersen, Astrid Louise Løvlie, Ketil Størdal, Trude Marie Lyngstad, Karoline Bragstad, Olav Hungnes, Lamprini Veneti

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

SARS-CoV-2 reinfection rates have been shown to vary depending on the circulating variant, vaccination status and background immunity, as well as the time interval used to identify reinfections. This study describes the frequency of SARS-CoV-2 reinfections in Norway using different time intervals and assesses potential factors that could impact the risk of reinfections during the different variant waves.

Methods

We used linked individual-level data from national registries to conduct a retrospective cohort study including all cases with a positive test for SARS-CoV-2 from February 2020 to January 2022. Time intervals of 30, 60, 90 or 180 days between positive tests were used to define potential reinfections. A multivariable Cox regression model was used to assess the risk of reinfection in terms of variants adjusting for vaccination status, demographic factors, and underlying comorbidities.

Results

The reinfection rate varied between 0.2%, 0.6% and 5.9% during the Alpha, Delta and early Omicron waves, respectively. In the multivariable model, younger age groups were associated with a higher risk of reinfection compared to older age groups, whereas vaccination was associated with protection against reinfection. Moreover, the risk of reinfection followed a pattern similar to risk of first infection. Individuals infected early in the pandemic had higher risk of reinfection than individuals infected in more recent waves.

Conclusions

Reinfections increased markedly during the Omicron wave. Younger individuals, and primary infections during earlier waves were associated with an increased reinfection risk compared to primary infections during more recent waves, whereas vaccination was a protective factor. Our results highlight the importance of age and post infection waning immunity and are relevant when evaluating vaccination polices.
Appendix
Available only for authorised users
Literature
1.
go back to reference To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. Clin Infect Dis. 2020;73(9):e2946–51.CrossRef To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. Clin Infect Dis. 2020;73(9):e2946–51.CrossRef
2.
go back to reference Flacco, M.E., C. Acuti Martellucci, V. Baccolini, C. De Vito, E. Renzi, P. Villari, et al., Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis. Eur J Clin Investig. 2022. 52(10): e13845. Flacco, M.E., C. Acuti Martellucci, V. Baccolini, C. De Vito, E. Renzi, P. Villari, et al., Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis. Eur J Clin Investig. 2022. 52(10): e13845.
3.
go back to reference Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect. 2021;27(3):315–8.CrossRefPubMed Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect. 2021;27(3):315–8.CrossRefPubMed
4.
go back to reference Bastard J, Taisne B, Figoni J, Mailles A, Durand J, Fayad M, et al. Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022. Eurosurveillance. 2022;27(13):2200247.CrossRefPubMedPubMedCentral Bastard J, Taisne B, Figoni J, Mailles A, Durand J, Fayad M, et al. Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022. Eurosurveillance. 2022;27(13):2200247.CrossRefPubMedPubMedCentral
5.
go back to reference Eythorsson E, Runolfsdottir HL, Ingvarsson RF, Sigurdsson MI, Palsson R. Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland. JAMA Network Open. 2022;5(8):e2225320–e2225320.CrossRefPubMedPubMedCentral Eythorsson E, Runolfsdottir HL, Ingvarsson RF, Sigurdsson MI, Palsson R. Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland. JAMA Network Open. 2022;5(8):e2225320–e2225320.CrossRefPubMedPubMedCentral
6.
go back to reference Medić S, Anastassopoulou C, Lozanov-Crvenković Z, Vuković V, Dragnić N, Petrović V, et al. Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study. Lancet Reg Health - Eur. 2022;20:100453.CrossRefPubMedPubMedCentral Medić S, Anastassopoulou C, Lozanov-Crvenković Z, Vuković V, Dragnić N, Petrović V, et al. Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study. Lancet Reg Health - Eur. 2022;20:100453.CrossRefPubMedPubMedCentral
7.
go back to reference Nguyen NN, Houhamdi L, Hoang VT, Delerce J, Delorme L, Colson P, et al. SARS-CoV-2 reinfection and COVID-19 severity. Emerg Microbes Infect. 2022;11(1):894–901.CrossRefPubMedPubMedCentral Nguyen NN, Houhamdi L, Hoang VT, Delerce J, Delorme L, Colson P, et al. SARS-CoV-2 reinfection and COVID-19 severity. Emerg Microbes Infect. 2022;11(1):894–901.CrossRefPubMedPubMedCentral
8.
go back to reference European Centre for Disease Prevention and Control, Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA. 8 April 2021, ECDC: Stockholm, 2021. European Centre for Disease Prevention and Control, Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA. 8 April 2021, ECDC: Stockholm, 2021.
10.
go back to reference Seppälä E, Tønnessen R, Veneti L, Paulsen TH, Steens A, Whittaker R, et al. COVID-19 cases reported to the Norwegian Institute of Public Health in the first six weeks of the epidemic. Tidsskr Nor Laegeforen. 2020;140(18). https://doi.org/10.4045/tidsskr.20.0525. English, Norwegian. Seppälä E, Tønnessen R, Veneti L, Paulsen TH, Steens A, Whittaker R, et al. COVID-19 cases reported to the Norwegian Institute of Public Health in the first six weeks of the epidemic. Tidsskr Nor Laegeforen. 2020;140(18). https://​doi.​org/​10.​4045/​tidsskr.​20.​0525. English, Norwegian.
14.
go back to reference Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Eurosurveillance. 2021;26(50):2101147.CrossRefPubMedPubMedCentral Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Eurosurveillance. 2021;26(50):2101147.CrossRefPubMedPubMedCentral
17.
go back to reference Veneti, L., B. Valcarcel Salamanca, E. Seppälä, J. Starrfelt, M.L. Storm, K. Bragstad, et al., No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway. Int J Infect Dis. 2022. 115: 178-184. Veneti, L., B. Valcarcel Salamanca, E. Seppälä, J. Starrfelt, M.L. Storm, K. Bragstad, et al., No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway. Int J Infect Dis. 2022. 115: 178-184.
18.
go back to reference Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114.CrossRefPubMed Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114.CrossRefPubMed
19.
go back to reference Veneti L, Berild JD, Watle SV, Starrfelt J, Greve-Isdahl M, Langlete P, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022. Int J Infect Dis. 2023;130:182–8.CrossRefPubMedPubMedCentral Veneti L, Berild JD, Watle SV, Starrfelt J, Greve-Isdahl M, Langlete P, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022. Int J Infect Dis. 2023;130:182–8.CrossRefPubMedPubMedCentral
24.
go back to reference Özüdoğru, O., Y.G. Bahçe, and Ö. Acer, SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants. Irish J Med Sci (1971 -), 2023. 192(2): 751-756. Özüdoğru, O., Y.G. Bahçe, and Ö. Acer, SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants. Irish J Med Sci (1971 -), 2023. 192(2): 751-756.
25.
go back to reference Nguyen NN, Houhamdi L, Hoang VT, Stoupan D, Fournier P-E, Raoult D, et al. High rate of reinfection with the SARS-CoV-2 Omicron variant. J Infect. 2022;85(2):174–211.CrossRefPubMedPubMedCentral Nguyen NN, Houhamdi L, Hoang VT, Stoupan D, Fournier P-E, Raoult D, et al. High rate of reinfection with the SARS-CoV-2 Omicron variant. J Infect. 2022;85(2):174–211.CrossRefPubMedPubMedCentral
26.
go back to reference Pulliam, J.R.C., C. van Schalkwyk, N. Govender, A. von Gottberg, C. Cohen, M.J. Groome, et al., Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science, 2022. 376(6593): eabn4947. Pulliam, J.R.C., C. van Schalkwyk, N. Govender, A. von Gottberg, C. Cohen, M.J. Groome, et al., Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science, 2022. 376(6593): eabn4947.
27.
go back to reference Syed AM, Ciling A, Taha TY, Chen IP, Khalid MM, Sreekumar B, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proc Natl Acad Sci. 2022;119(31):e2200592119.CrossRefPubMedPubMedCentral Syed AM, Ciling A, Taha TY, Chen IP, Khalid MM, Sreekumar B, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proc Natl Acad Sci. 2022;119(31):e2200592119.CrossRefPubMedPubMedCentral
28.
go back to reference Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021;602(7898):671–5.CrossRefPubMed Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021;602(7898):671–5.CrossRefPubMed
29.
go back to reference Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022;399(10325):625–6.CrossRefPubMedPubMedCentral Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022;399(10325):625–6.CrossRefPubMedPubMedCentral
30.
go back to reference Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022;386(13):1288–90.CrossRefPubMed Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022;386(13):1288–90.CrossRefPubMed
31.
go back to reference Starrfelt J, Danielsen AS, Buanes EA, Juvet LK, Lyngstad TM, Rø GØI, et al. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021. BMC Med. 2022;20(1):278.CrossRefPubMedPubMedCentral Starrfelt J, Danielsen AS, Buanes EA, Juvet LK, Lyngstad TM, Rø GØI, et al. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021. BMC Med. 2022;20(1):278.CrossRefPubMedPubMedCentral
32.
go back to reference Mensah AA, Lacy J, Stowe J, Seghezzo G, Sachdeva R, Simmons R, et al. Disease severity during SARS-COV-2 reinfection: a nationwide study. J Infect. 2022;84(4):542–50.CrossRefPubMedPubMedCentral Mensah AA, Lacy J, Stowe J, Seghezzo G, Sachdeva R, Simmons R, et al. Disease severity during SARS-COV-2 reinfection: a nationwide study. J Infect. 2022;84(4):542–50.CrossRefPubMedPubMedCentral
33.
go back to reference Spicer KB, Glick C, Cavanaugh AM, Thoroughman D. Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) – Kentucky, USA, 2020. Int J Infect Dis. 2022;114:21–8.CrossRefPubMed Spicer KB, Glick C, Cavanaugh AM, Thoroughman D. Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) – Kentucky, USA, 2020. Int J Infect Dis. 2022;114:21–8.CrossRefPubMed
35.
go back to reference Veneti, L., H. Bøås, A. Bråthen Kristoffersen, J. Stålcrantz, K. Bragstad, O. Hungnes, et al., Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Eurosurveillance, 2022. 27(4): 2200077. Veneti, L., H. Bøås, A. Bråthen Kristoffersen, J. Stålcrantz, K. Bragstad, O. Hungnes, et al., Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Eurosurveillance, 2022. 27(4): 2200077.
40.
go back to reference Herrera-Esposito, D. and G. de Los Campos, Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. BMC Infect Dis, 2022. 22(1): 311. Herrera-Esposito, D. and G. de Los Campos, Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. BMC Infect Dis, 2022. 22(1): 311.
41.
go back to reference Indseth, T., A.A. Godøy, M.K.R. Kjøllesdal, T.M. Arnesen, C.C. Jacobsen, K.H. Vinjerui, et al., Covid-19 etter fødeland fra mars 2020 til februar 2021, in Covid-19 by country March 2020-February 2021. 2021, Folkehelseinstituttet, Område for helsetjeneste og Område for smittevern. Indseth, T., A.A. Godøy, M.K.R. Kjøllesdal, T.M. Arnesen, C.C. Jacobsen, K.H. Vinjerui, et al., Covid-19 etter fødeland fra mars 2020 til februar 2021, in Covid-19 by country March 2020-February 2021. 2021, Folkehelseinstituttet, Område for helsetjeneste og Område for smittevern.
42.
go back to reference Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023;401(10379):833–42.CrossRef Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023;401(10379):833–42.CrossRef
Metadata
Title
Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022
Authors
Håkon Bøås
Margrethe Larsdatter Storm
German Tapia
Anja Bråthen Kristoffersen
Astrid Louise Løvlie
Ketil Størdal
Trude Marie Lyngstad
Karoline Bragstad
Olav Hungnes
Lamprini Veneti
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-17695-8

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue